Brief: Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma
17/03/2025 11:09
March 17 (Reuters) - Perspective Therapeutics Inc CATX.A: PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH 212PBVMT01 IN COMBINATION WITH NIVOLUMAB IN A PHASE 1/2A STUDY OF MC1R-POSITIVE METASTATIC MELANOMA Source text: ID:nGNX3HBbxM Further company coverage: CATX.A ((Reuters.Briefs@thomsonreuters.com))
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise